SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN)
ALXN 182.500.0%Jul 28 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (250)11/18/2002 10:56:45 AM
From: keokalani'nui  Read Replies (2) of 824
 
It looks like lytic, just in the US, was nearly significant for mortality. With lower incidence of revascularization outside US and non-US patients coming in on death's door, these differences would have a legitimate effect on the numbers.

As for significant 70% mortality benefit in PCI, this is much more than hoped. Still, I can not understand why there is not ckmb correlation.

Also appears PnG still involved. I can't see how they would abandon pexeli now.

Breathing bigass sigh of relief.

No one better post this on biotech failures!!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News